Our website is made possible by displaying online advertisements to our visitors.
Please consider supporting us by disabling your ad blocker.
Cervarix
| Vaccine description | |
|---|---|
| Target | human papillomavirus (Types 16 and 18) |
| Vaccine type | Protein subunit |
| Clinical data | |
| Trade names | Cervarix |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a610014 |
| Routes of administration | Intramuscular injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  (what is this?) (verify) | |
Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV).
Cervarix is designed to prevent infection from HPV types 16 and 18, that cause about 70% of cervical cancer cases.[6] These types also cause most HPV-induced genital and head and neck cancers. Additionally, some cross-reactive protection against virus strains 45 and 31 were shown in clinical trials.[7] Cervarix also contains AS04, a proprietary adjuvant that has been found to boost the immune system response for a longer period of time.[8]
Cervarix is manufactured by GlaxoSmithKline. An alternative product, from Merck & Co., is known as Gardasil.[6] Cervarix was voluntarily taken off of the market in the US in 2016 due to low demand.[9]
- ^ "CERVARIX human papillomavirus vaccine types 16 and 18 [recombinant, AS04 adjuvanted] suspension for injection vial (126115)". department of Health and Aged Care.
- ^ "Archived copy" (PDF). Archived (PDF) from the original on 1 May 2022. Retrieved 10 October 2022.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Cervarix". U.S. Food and Drug Administration (FDA). 4 October 2022. STN:BL 125259. Archived from the original on 10 October 2022. Retrieved 9 October 2022.
- ^ "Cervarix". U.S. Food and Drug Administration (FDA). 16 October 2009. Archived from the original on 22 July 2017. Retrieved 9 October 2022.
- ^ "Cervarix EPAR". European Medicines Agency (EMA). 23 December 2008. Archived from the original on 5 June 2022. Retrieved 9 October 2022.
- ^ a b Centers for Disease Control and Prevention (CDC) (May 2010). "FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)". MMWR. Morbidity and Mortality Weekly Report. 59 (20): 626–629. PMID 20508593. Archived from the original on 3 August 2017. Retrieved 9 September 2017.
- ^ "New data show Cervarix, GSK'S HPV 16/18 cervical cancer candidate vaccine, is highly immunogenic and well-tolerated in women over 25 years of age". GlaxoSmithKline. 5 June 2006. Archived from the original on 27 September 2007. Retrieved 27 January 2007.
- ^ "Cervical Cancer Vaccines: Cervarix". Emory University. 21 August 2006. Archived from the original on 9 October 2006. Retrieved 27 January 2007.
- ^ "GSK exits U.S. market with its HPV vaccine Cervarix". FiercePharma. 21 October 2016. Archived from the original on 9 July 2021. Retrieved 6 July 2021.
Previous Page Next Page
